Search
-
Annual Report 2022
Media
https://www.gsk.com/media/9956/annual-report-2022.pdf
First published: 10 March 2023
-
20-F 2022
Media
https://www.gsk.com/media/9974/20-f-2022.pdf
First published: 10 March 2023
-
Annual Report 2014
Media
https://www.gsk.com/media/8088/annual-report-2014.pdf
First published: 01 June 2022
-
Annual Report 2023
Media
https://www.gsk.com/media/11007/annual-report-2023.pdf
First published: 01 March 2024
-
2023 Annual Report On Form 20 F
Media
https://www.gsk.com/media/11018/2023-annual-report-on-form-20-f.pdf
First published: 05 March 2024
-
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Media
Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-n6ls/
First published: 25 October 2022
-
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
Media
Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/
First published: 09 March 2021
-
GSK receives marketing authorisation from the European Commission for additional Revolade™
Media
GSK announced that the EC has granted Revolade™ as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection.
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-revolade/
First published: 24 September 2013
-
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®
Media
The UK is now one of the leading countries in stockpiling antivirals for treating infected individuals in event of an influenza pandemic
https://www.gsk.com/en-gb/media/press-releases/the-uk-government-signs-influenza-pandemic-contract-with-glaxosmithkline-for-relenza/
First published: 28 January 2009
-
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
Media
GSK announced a positive opinion from EMA's CHMP recommending marketing authorisation for Revolade™ (eltrombopag).
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-revolade-in-thrombocytopenia-associated-with-chronic-hepatitis-c-infection/
First published: 26 July 2013